ANGLE plc
Notice of Results
GUILDFORD, SURREY--(Marketwired - Jan 10, 2018) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)
For Immediate Release | 10 January 2018 |
ANGLE plc
("ANGLE" or "the Company")
Notification of Interim Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 31 October 2017 on Wednesday 31 January 2018.
A meeting for analysts will be held at 10.30am on 31 January 2018 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.
A live webcast of the analyst meeting will also be available on ANGLE's Investor Centre page, http://www.angleplc.com/investor-information/investor-centre/. Please log on to the web address approximately 5 minutes before 10.30 am on the day of the results.
A recording of the webcast will also be made available on ANGLE's website, www.ANGLEplc.com, following the results meeting.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain |
+44 (0) 20 7220 0500 |
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee |
+44 (0) 203 705 9330 |
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Kimberly Ha (US) |
+44 (0) 203 727 1000 +1 212 850 5612 |
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.